Clobenpropit dihydrobromide, H3 antagonist (ab120780)
Key features and details
- Selective H3 antagonist
- CAS Number: 145231-35-2
- Purity: > 99%
- Soluble in water to 100 mM
- Form / State: Solid
- Source: Synthetic
製品の概要
-
製品名
Clobenpropit dihydrobromide, H3 antagonist -
製品の詳細
Selective H3 antagonist -
生理活性の詳細
Selective and competitive H3 antagonist (pKi = 8.5). Partial agonist at H4 receptor (EC50 = 3 nM) Blood-brain barrier permeable.
-
精製度
> 99% -
CAS 番号
145231-35-2 -
構造式
製品の特性
-
体系名
N-(4-Chlorobenzyl)-S-[3-(4(5)-imidazolyl)propyl]isothiourea dihydrobromide -
分子量
470.65 -
分子式
C14H17ClN4S.2HBr -
保存方法
Store at Room Temperature. The product can be stored for up to 12 months. -
溶解性
Soluble in water to 100 mM -
使用に関する注意
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
由来
Synthetic
-
研究分野
プロトコール
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
参考文献 (3)
ab120780 は 3 報の論文で使用されています。
- Hansen KB et al. Implementation of a fluorescence-based screening assay identifies histamine H3 receptor antagonists clobenpropit and iodophenpropit as subunit-selective N-methyl-D-aspartate receptor antagonists. J Pharmacol Exp Ther 333:650-62 (2010). PubMed: 20197375
- Dai H et al. The histamine H3 receptor antagonist clobenpropit enhances GABA release to protect against NMDA-induced excitotoxicity through the cAMP/protein kinase A pathway in cultured cortical neurons. Eur J Pharmacol 563:117-23 (2007). PubMed: 17350613
- Buckland KF et al. Histamine induces cytoskeletal changes in human eosinophils via the H(4) receptor. Br J Pharmacol 140:1117-27 (2003). PubMed: 14530216